Feroxyma Ingredients and Usage

The active ingredient is Ferric Carboxymaltose, a stable complex of ferric iron and carboxymaltose. It is administered as a single intravenous dose up to 1000mg (20ml) by slow injection or diluted infusion, typically over at least 15 minutes, under medical supervision.

Feroxyma is clinically indicated for:

• Iron deficiency anemia when oral iron is ineffective or poorly tolerated
• Iron deficiency in chronic kidney disease patients
• Postpartum iron deficiency anemia
• Heavy menstrual bleeding-associated anemia
• Inflammatory bowel disease with iron deficiency

How Does Feroxyma Work?

Feroxyma provides rapid iron repletion through controlled iron release:

1. Stable Complex Formation: Iron is tightly bound to carboxymaltose preventing free iron release
2. Targeted Delivery: Administered intravenously for 100% bioavailability
3. Macrophage Processing: Taken up by reticuloendothelial system macrophages
4. Controlled Iron Release: Slowly releases iron to transferrin for hemoglobin synthesis

Feroxyma Side Effects and Warnings

Common side effects include nausea, headache, dizziness, hypertension, hypophosphatemia, and injection site reactions. Most reactions are mild and transient.

Serious Considerations

1. Hypersensitivity Reactions: May cause serious anaphylactic reactions – administer in monitored settings
2. Hypophosphatemia: Can cause significant and sometimes prolonged hypophosphatemia
3. Hypertension: Transient hypertension may occur during administration
4. Overload Risk: Contraindicated in patients with iron overload syndromes
5. Oxidative Stress: Potential for increased oxidative stress due to iron administration

Feroxyma Storage Conditions

Feroxyma Injection requires proper storage conditions:

• Store below 25°C in original carton
• Protect from light and freezing
• Use immediately after opening
• Do not use if solution is discolored or contains particles
• Keep out of reach of children